<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04623281</url>
  </required_header>
  <id_info>
    <org_study_id>HOPE-02</org_study_id>
    <nct_id>NCT04623281</nct_id>
  </id_info>
  <brief_title>Haemodialysis Outcomes &amp; Patient Empowerment Study 02</brief_title>
  <acronym>HOPE-02</acronym>
  <official_title>Haemodialysis Outcomes &amp; Patient Empowerment Study 02</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal College of Surgeons, Ireland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beaumont Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>patientMpower Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Design to Value Ltd</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Enterprise Ireland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Royal College of Surgeons, Ireland</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pilot-scale, single-arm,observational study to assess the utility and acceptability of a&#xD;
      wearable hydration monitor in haemodialysis patients compared with bioimpedance and&#xD;
      haemodialysis machine data.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pilot-scale, single-arm,observational study to assess the utility and acceptability of a&#xD;
      wearable hydration monitor in haemodialysis patients compared with bioimpedance and&#xD;
      haemodialysis machine data.&#xD;
&#xD;
      The Sixty device uses diffuse reflectance spectroscopy to measure fluid status.&#xD;
&#xD;
      20 patients will be assessed during the study observation period.&#xD;
&#xD;
      10 patients undergo an observation period of approximately three weeks. The patients will be&#xD;
      asked to wear the Sixty device during dialysis and at night throughout the study observation&#xD;
      period.&#xD;
&#xD;
      Following the completion of this 3 week observation period, an additional 10 patients will&#xD;
      wear the Sixty device as per the protocol for 3 weeks.&#xD;
&#xD;
      Haemodialysis parameters will be assessed as usual during the study.&#xD;
&#xD;
      Bioimpedance measurements will be taken pre and post-dialysis once weekly during the mid-week&#xD;
      dialysis session:&#xD;
&#xD;
      Patient-reported symptoms related to haemodialysis will be recorded, including symptoms of&#xD;
      hypervolaemia and hypovolaemia.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 21, 2021</start_date>
  <completion_date type="Actual">June 15, 2021</completion_date>
  <primary_completion_date type="Actual">June 15, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of Sixty device versus bioimpedance</measure>
    <time_frame>3 weeks</time_frame>
    <description>The primary endpoint will be to evaluate the accuracy of the Sixty device data in assessing volume in haemodialysis patients compared to bioimpedance&#xD;
Bioimpedance measurements will be performed using the Fresenius Body Composition Monitor (BCM)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of changes in volume status as determined by Sixty device versus fluid removed per unit of time during haemodialysis session</measure>
    <time_frame>3 weeks</time_frame>
    <description>Fluid removed (mls/ unit of time)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of changes in volume status as determined by Sixty device versus blood pressure</measure>
    <time_frame>3 weeks</time_frame>
    <description>Blood pressure (mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of changes in volume status as determined by Sixty device versus change in weight pre and post dialysis</measure>
    <time_frame>3 weeks</time_frame>
    <description>Weight (kg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of changes in volume status as determined by Sixty device versus change in blood volume monitoring</measure>
    <time_frame>3 weeks</time_frame>
    <description>Blood volume monitoring: Relative blood volume (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability of Sixty device</measure>
    <time_frame>3 weeks</time_frame>
    <description>The patient's opinion of the acceptability of the Sixty device as assessed by their response to a questionnaire.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">20</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Dialysis; Complications</condition>
  <condition>Volume Overload</condition>
  <arm_group>
    <arm_group_label>Observational group</arm_group_label>
    <description>Observational group of 10 haemodialysis patients following usual care for 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sixty device</intervention_name>
    <description>Prototype wearable hydration monitor to be worn by patient during dialysis and at night</description>
    <arm_group_label>Observational group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Require maintenance haemodialysis in an ambulatory care setting. Study will be conducted in&#xD;
        a single centre in a tertiary hospital. Patients with a range of baseline fluid statuses&#xD;
        will be considered for enrollment.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  On haemodialysis in an ambulatory care setting.&#xD;
&#xD;
          -  Demonstrates understanding of correct use of the Sixty device.&#xD;
&#xD;
          -  Capable and willing to measure blood pressure at home on a daily basis.&#xD;
&#xD;
          -  Willing to give written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Conditions precluding use of bioimpedance (e.g. Implantable Cardioverter&#xD;
             Defibrillator, pacemakers, hearing aids, pregnancy).&#xD;
&#xD;
          -  Significant confusion or any concomitant medical condition, which would limit the&#xD;
             ability of the patient to record symptoms or other parameters.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Renal Dialysis Centre, Beaumont Hospital</last_name>
    <role>Principal Investigator</role>
    <affiliation>RCSI</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <state>Leinster</state>
        <zip>9</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 23, 2020</study_first_submitted>
  <study_first_submitted_qc>November 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 10, 2020</study_first_posted>
  <last_update_submitted>September 2, 2021</last_update_submitted>
  <last_update_submitted_qc>September 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sensor</keyword>
  <keyword>Volume Overload</keyword>
  <keyword>Dialysis</keyword>
  <keyword>Bioimpedance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 26, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/81/NCT04623281/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

